Novavax (NVAX)
(Delayed Data from NSDQ)
$4.09 USD
+0.14 (3.54%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $4.07 -0.02 (-0.49%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NVAX 4.09 +0.14(3.54%)
Will NVAX be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for NVAX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NVAX
How Should You Play Merck (MRK) Stock Ahead of Q1 Earnings?
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
NVAX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Want Better Returns? Don?t Ignore These 2 Medical Stocks Set to Beat Earnings
What's in Store for Biogen (BIIB) This Earnings Season?
J&J (JNJ) to Begin Pharma Q1 Earnings Season: What's in Store?
Other News for NVAX
Novavax Inc. stock outperforms competitors on strong trading day
Novavax prepared to deliver JN.1 COVID vaccine in line with WHO recommendation
Novavax Inc. stock underperforms Thursday when compared to competitors
3 Biotech Stocks That Could Be Multibaggers in the Making: April Edition
Novavax Inc. stock underperforms Wednesday when compared to competitors